citation_journal,link,PMID
"Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid‐β assessed by florbetapir F 18 PET and 18‐month cognitive decline: a multicenter study.  Neurology 2012;79(16):1636‐44. CENTRAL    PubMed     Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/22786606,22786606
"Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative. Comparison of visual and quantitative Florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes.  JAMA Neurology 2015;72(10):1183‐90. CENTRAL    PubMed     Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/26280102,26280102
"Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. Florbetapir F 18 amyloid PET and 36‐month cognitive decline: a prospective multicenter study.  Molecular Psychiatry 2014;19(9):1044‐51.  CENTRAL   PubMed     Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/24614494,24614494
"Kawas CH, Greenia DE, Bullain SS, Clark CM, Pontecorvo MJ, Joshi AD, et al. Amyloid imaging and cognitive decline in nondemented oldest‐old: the 90+ study.  Alzheimer's & Dementia 2013;9(2):199‐203. CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23164550,23164550
"Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.  Alzheimer's & Dementia 2013;9 Suppl(5):S72‐83. CENTRAL    Google Scholar",https://www.ncbi.nlm.nih.gov/pubmed/23375563,23375563
